Table 2.
Variables | Total (n=376) |
Development Set (n=301) | Validation Set (n=75) | Statistics | P value |
---|---|---|---|---|---|
Age | 0.016 | 0.899 | |||
<20 years | 173(46.0%) | 138(45.8%) | 35(46.7%) | ||
≥20 years | 203(54.0%) | 163(54.2%) | 40(53.3%) | ||
Gender | 0.674 | 0.412 | |||
Male | 236(62.8%) | 192(63.8%) | 44(58.7%) | ||
Female | 140(37.2%) | 109(36.2%) | 31(41.3%) | ||
NLR | 0.326 | 0.568 | |||
<3.4 | 120(31.9%) | 94(31.2%) | 26(34.7%) | ||
≥3.4 | 256(68.1%) | 207(68.8%) | 49(65.3%) | ||
PLR | 1.777 | 0.182 | |||
<171 | 369(98.1%) | 294(97.7%) | 75(100.0%) | ||
≥171 | 7(1.9%) | 7(2.3%) | 0(0.0%) | ||
Metastasis | 0.032 | 0.858 | |||
Lung only | 152(40.4%) | 121(40.2%) | 31(41.3%) | ||
Lung and other sites | 224(59.6%) | 180(59.8%) | 44(58.7%) | ||
Tumor site | 1.906 | 0.167 | |||
Axial skeleton | 217(57.7%) | 179(59.5%) | 38(50.7%) | ||
Extremity | 159(42.3%) | 122(40.5%) | 37(49.3%) | ||
Tumor size (median/interquartile range, cm) | 18.0(5.4–28.8) | 18.3(5.4–28.8) | 17.1(5.7–28.2) | 0.000 | 0.996 |
ALP | 0.983 | 0.321 | |||
Normal (<154 IU/L) | 315(83.8%) | 255(84.7%) | 60(80.0%) | ||
Elevated (≥154 IU/L) | 61(16.2%) | 46(15.3%) | 15(20.0%) | ||
Anti-angiogenesis therapy | 1.154 | 0.283 | |||
No | 334(88.8%) | 270(89.7%) | 64(85.3%) | ||
Yes | 42(11.2%) | 31(10.3%) | 11(14.7%) | ||
CD4+/CD8+ ratio | 1.230 | 0.267 | |||
High (≥3.27) | 315(83.8%) | 249(82.7%) | 66(88.0%) | ||
Low (<3.27) | 61(16.2%) | 52(17.3%) | 9(12.0%) | ||
Chemotherapy | 0.965 | 0.326 | |||
≥6 cycles | 70(18.6%) | 59(19.6%) | 11(14.7%) | ||
<6 cycles | 306(81.4%) | 242(80.4%) | 64(85.3%) | ||
CONUT score | 0.065 | 0.968 | |||
Normal | 17(4.5%) | 14(4.7%) | 3(4.0%) | ||
Mild+moderate | 233(62.0%) | 186(61.8%) | 47(62.7%) | ||
Severe | 126(33.5%) | 101(33.6%) | 25(33.3%) |
Abbreviations: NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; ALP, alkaline phosphatase; CD, cluster of differentiation; CONUT score, controlling nutritional status score.